Clinical trial
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients…
NCT00076986 · INSYS Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00076986 |
|---|---|
| Title | The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme |
| Official title | PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence |
| Lead sponsor | INSYS Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug, Procedure |
| Interventions | IL13-PE38QQR, surgery and catheter placement (2 procedures), prolifespan 20 with carmustine implant (GLIADEL® Wafer), surgery and wafer placement (1 procedure) |
| Enrollment | 300 |
| Start date | Feb 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Feb 10, 2004 |
| Last update posted | Jun 6, 2011 |
| Countries | Canada, Germany, Israel, Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: